Comparison · NCT00326781-d5475111
Transdermal Nicotine vs Nicotine Nasal Spray: Verified 7-day Point Prevalence Abstinence at End Of Treatment.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Transdermal Nicotine vs Nicotine Nasal Spray: Verified 7-day Point Prevalence Abstinence at End Of Treatment. Trial comparisons, record NCT00326781-d5475111. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00326781-d5475111
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.326 | 0.278 | 0.377 | wilson | |
| Risk in group 2 | 0.288 | 0.242 | 0.339 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0377 | -0.0319 | 0.107 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.13 | 0.901 | 1.42 | log | |
| Odds ratio, group 1 over group 2 | 1.19 | 0.86 | 1.66 | log | |
| Number needed to treat, for one more participant with the outcome on Transdermal Nicotine than on Nicotine Nasal Spray | 26.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Transdermal Nicotine | Half of randomized participants received 8-weeks of transdermal nicotine (Nicoderm CQ). The dosing schedule was as follows: 4 weeks of 21mg per 24 hours, 2 weeks of 14mg per 24 hours, and 2 weeks of 7mg per 24 hours. | 112 | 344 | OG000 |
| Group 2 | Nicotine Nasal Spray | Half of all participants received nicotine nasal spray. 8 weeks of self-administered nicotine nasal spray @ 40 recommended doses per day, tapering by 1/3 for the last 4 weeks. Nasal spray dosing was 0.5 mg spray per nostril (1 mg) for a maximum of 5 doses per hour and 40 doses per day. This dosing schedule is based on the average nicotine intake per cigarette of 1 mg per cigarette. | 95 | 330 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Verified 7-day Point Prevalence Abstinence at End Of Treatment.
- Description
End-of-Treatment (EOT) is defined as the phone survey that takes place at the end of each subject's nicotine replacement therapy treatment. The EOT took place up to 8 weeks after participants began the study and also utilized the Timeline Followback. It is a 7-day point prevalence measure describing a subject's ability to remain abstinent from smoking for the 7 previous days occurring before a subject's EOT phone survey.~This was verified by a Carbon Monoxide breath reading taking place within a week of a subject's End of Treatment phone survey.
- Time frame
- End of Treatment
- Population
Source ClinicalTrials.gov
Trial
- Title
- Bio-Behavioral Predictors of the Efficacy of Nicotine Replacement Therapy (NRT)
- NCT number
- NCT00326781
- Phases
- PHASE4
- Conditions
- Smoking
- Interventions
- Nicoderm Transdermal Patch, Nicotine Nasal Spray
- Lead sponsor
- University of Pennsylvania
- Results first posted
- 2010-03-19
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00326781?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00326781-d5475111